title: [Safety and immunogenicity of the diphtheria, tetanus, accellular pertussis plus hemophilus influenza type b combined vaccine (DTaP-Hib) to Chinese infants].
abstract: OBJECTIVE
  To evaluate the safety and immunogenicity of combined diphtheria, tetanus, accellular pertussis Plus hemophilus influenza type b vaccine (DTaP-Hib)to Chinese infants.
  
  
  METHODS
  Safety study (study A), and immunogenicity and safety study (study B) were conducted in infants aged 3, 4 and 5 months. The immune response and safety of the DTaP-Hib vaccine were compared after administered DTaP and Hib separately based on specified criteria.
  
  
  RESULTS
  A total of 690 healthy infants received primary vaccination with combined DTaP-Hib or administered DTaP and Hib(DTaP+Hib) separately. Immunogenicity was assessed before and one month after vaccination in a subjet. The tolerance of DTaP-Hib vaccine was at least as same as administered DTaP+Hib separately. The differences of local and general adverse events following immunigation (AEFI) between groups had no difference statisticaly significantly. At least 97.5% of DTaP-Hib recipients had seroprotection against diphtheria, tetanus and Hib, and response to acellular pertussis antigens one month after primary vaccination. The immune response of the DTaP-Hib vaccine was comparable to administered DTaP+Hib based on specified criteria separately.
  
  
  CONCLUSIONS
  The combined DTaP-Hib vaccine gets expected safety and immunogenicity.
authors.affiliation: Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning 530028, Guangxi Zhuang Autonomous Region, China.
authors.forename: Yan-ping
authors.initials: YP
authors.lastname: Li
authors.forename: Shu-min
authors.initials: SM
authors.lastname: Zhang
authors.forename: Qiang
authors.initials: Q
authors.lastname: Ye
mesh_terms: D000917:Antibody Formation / Q000276:immunology; D044466:Asian People; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D064420:Drug-Related Side Effects and Adverse Reactions; D019741:Haemophilus influenzae type b / Q000276:immunology*; D006801:Humans; D007223:Infant; D013997:Time Factors
chemical_list: D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines